{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T19:00:29Z","timestamp":1772305229327,"version":"3.50.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2009,10,18]],"date-time":"2009-10-18T00:00:00Z","timestamp":1255824000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1007\/s11606-009-1037-2","type":"journal-article","created":{"date-parts":[[2009,10,17]],"date-time":"2009-10-17T01:29:10Z","timestamp":1255742950000},"page":"383-388","source":"Crossref","is-referenced-by-count":20,"title":["The Expanding Use of Third-Generation Aromatase Inhibitors: What the General Internist Needs to Know"],"prefix":"10.1007","volume":"24","author":[{"given":"Susan","family":"Hong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aarati","family":"Didwania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olufunmilayo","family":"Olopade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Ganschow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,10,18]]},"reference":[{"issue":"1","key":"1037_CR1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1200\/JCO.2003.03.088","volume":"21","author":"CI Li","year":"2003","unstructured":"Li CI, Daling JR, Malone KE. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol. 2003;21(1):28\u201334.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1037_CR2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdm282","volume":"19","author":"HS Rugo","year":"2008","unstructured":"Rugo HS. The breast cancer continuum in hormone-receptor positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol. 2008;19(1):16\u201327.","journal-title":"Ann Oncol"},{"issue":"1","key":"1037_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2007.03.016","volume":"256","author":"RB Riggins","year":"2007","unstructured":"Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH. Pathways to tamoxifen resistance. Cancer Letters. 2007;256(1):1\u201324.","journal-title":"Cancer Letters"},{"key":"1037_CR4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1677\/erc.1.00776","volume":"11","author":"A Ring","year":"2004","unstructured":"Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocrine-Related Cancer. 2004;11:643\u201358.","journal-title":"Endocrine-Related Cancer"},{"issue":"12","key":"1037_CR5","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1111\/j.1742-1241.2007.01587.x","volume":"61","author":"CJ Fabian","year":"2007","unstructured":"Fabian CJ. The what, why and how of aromatase inhibitors:hormonal agents for treatment and prevention of breast cancer. Int J Clin Pract. 2007;61(12):2051\u201363.","journal-title":"Int J Clin Pract"},{"issue":"9","key":"1037_CR6","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/cncr.11745","volume":"98","author":"M Baum","year":"2003","unstructured":"Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early- stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003;98(9):1802\u201310.","journal-title":"Cancer"},{"issue":"11","key":"1037_CR7","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","volume":"350","author":"RC Coombes","year":"2004","unstructured":"Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350(11):1081\u201392.","journal-title":"N Engl J Med"},{"issue":"17","key":"1037_CR8","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/jnci\/dji250","volume":"97","author":"PE Goss","year":"2005","unstructured":"Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262\u201371.","journal-title":"J Natl Cancer Inst"},{"issue":"3\u20135","key":"1037_CR9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0960-0760(03)00378-9","volume":"86","author":"PE Goss","year":"2003","unstructured":"Goss PE. Breast cancer prevention\u2013clinical trials strategies involving aromatase inhibitors. J Steroid Biochem Mol Biol. 2003;86(3\u20135):487\u201393.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"Suppl 1","key":"1037_CR10","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.breast.2004.09.003","volume":"13","author":"F Janicke","year":"2004","unstructured":"Janicke F. Are all aromatase inhibitors the same? A review of the current evidence. Breast. 2004;13(Suppl 1):S10\u20138.","journal-title":"Breast"},{"issue":"1","key":"1037_CR11","first-page":"CD003370","volume":"24","author":"L Gibson","year":"2007","unstructured":"Gibson L, Dawson CK, Lawrence DH, Bliss JM. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database of Syst Rev. 2007;24(1):CD003370.","journal-title":"Cochrane Database of Syst Rev."},{"issue":"12","key":"1037_CR12","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S1470-2045(06)70948-2","volume":"7","author":"W Jonat","year":"2006","unstructured":"Jonat W, Gnant M, Boccardo F, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. The Lancet Oncol. 2006;7(12):991\u20136.","journal-title":"The Lancet Oncol"},{"key":"1037_CR13","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","volume":"25","author":"AS Coates","year":"2007","unstructured":"Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1\u201398. J Clin Oncol. 2007;25:486\u201392.","journal-title":"J Clin Oncol"},{"key":"1037_CR14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10549-007-9698-1","volume":"105","author":"PE Goss","year":"2007","unstructured":"Goss PE. Letrozole in the extended adjuvant setting: MA.17. Breast Cancer Res Treat. 2007;105:45\u201353.","journal-title":"Breast Cancer Res Treat"},{"key":"1037_CR15","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1200\/JCO.2007.14.0228","volume":"26","author":"E Mamounas","year":"2008","unstructured":"Mamounas E, Jeong J-H, Wickerman L, et al. Benefit from exemestane as extended adjuvant therapy after 5\u00a0years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol. 2008;26:1965\u201371.","journal-title":"J Clin Oncol"},{"key":"1037_CR16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10549-008-0129-8","volume":"112","author":"PE Goss","year":"2008","unstructured":"Goss PE. Extending the benefits of adjuvant therapy in early HR\u00a0+\u00a0breast cancer. Breast Cancer Res Treat. 2008;112:45\u201352.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"1037_CR17","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/archinte.165.5.552","volume":"165","author":"Z Chen","year":"2005","unstructured":"Chen Z, Maricic M, Bassford TL, et al. Fracture Risk Among Breast Cancer Survivors: Results From the Women\u2019s Health Initiative Observational Study. Arch Intern Med. 2005;165(5):552\u20138.","journal-title":"Arch Intern Med"},{"issue":"7","key":"1037_CR18","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/cncr.21335","volume":"104","author":"Z Chen","year":"2005","unstructured":"Chen Z, Maricic M, Pettinger M, et al. Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer. Cancer. 2005;104(7):1520\u201330.","journal-title":"Cancer"},{"key":"1037_CR19","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.bjc.6690188","volume":"79","author":"JA Kanis","year":"1999","unstructured":"Kanis JA, McCloskey EV, Powles T, Paterson AHG, Ashley S, Spector T. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer. 1999;79:1179\u201381.","journal-title":"Br J Cancer"},{"issue":"2","key":"1037_CR20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0169-6009(08)80220-6","volume":"22","author":"RL Ward","year":"1993","unstructured":"Ward RL, Morgan G, Dalley D, et al. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women Effects of exemestane administered for 2\u00a0years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. Bone Miner. 1993;22(2):87\u201394.","journal-title":"Bone Miner"},{"issue":"33","key":"1037_CR21","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1200\/JCO.2006.07.5382","volume":"24","author":"AJ Chien","year":"2006","unstructured":"Chien AJ, Goss PE. Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol. 2006;24(33):5305\u201312.","journal-title":"J Clin Oncol"},{"issue":"17","key":"1037_CR22","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1016\/j.ejca.2007.08.029","volume":"43","author":"EV McCloskey","year":"2007","unstructured":"McCloskey EV, Hannon RA, Lakner G, et al. Effects of third generation aromatase inhibitors on bone health and other safety parameters: Results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. European Journal of Cancer. 2007;43(17):2523\u201331.","journal-title":"European Journal of Cancer"},{"key":"1037_CR23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.breast.2007.10.004","volume":"16","author":"P Hadji","year":"2007","unstructured":"Hadji P. Reducing the risk of bone loss associated with breast cancer treatment. The Breast. 2007;16:10\u20135.","journal-title":"The Breast"},{"issue":"21","key":"1037_CR24","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","volume":"21","author":"BE Hillner","year":"2003","unstructured":"Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer. J Clin Oncol. 2003;21(21):4042\u201357.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1037_CR25","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archinte.164.10.1108","volume":"164","author":"ES Siris","year":"2004","unstructured":"Siris ES, Chen Y-T, Abbott TA, et al. Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures. Arch Intern Med. 2004;164(10):1108\u201312.","journal-title":"Arch Intern Med"},{"key":"1037_CR26","unstructured":"Clinician\u2019s guide to prevention and treatment of osteoporosis. 2008. (Accessed May 13, 2009, at http:\/\/www.nof.org\/professionals\/clinicians_guide.htm .)"},{"key":"1037_CR27","unstructured":"Fracture Risk Assessment Tool. (Accessed May 13, 2009, at http:\/\/www.shef.ac.uk\/FRAX\/ .)"},{"issue":"7","key":"1037_CR28","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","volume":"25","author":"A Brufsky","year":"2007","unstructured":"Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole- induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007;25(7):829\u201336. Epub 2006 Dec 11.","journal-title":"J Clin Oncol"},{"issue":"33","key":"1037_CR29","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1200\/JCO.2008.17.7451","volume":"26","author":"PM Camacho","year":"2008","unstructured":"Camacho PM, Dayal AS, Diaz JL, et al. Prevalence of Secondary Causes of Bone Loss Among Breast Cancer Patients With Osteopenia and Osteoporosis. J Clin Oncol. 2008;26(33):5380\u20135.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1037_CR30","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1200\/JCO.2001.19.10.2767","volume":"19","author":"PP Donnellan","year":"2001","unstructured":"Donnellan PP, Douglas SL, Cameron DA, Leonard RC. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001;19(10):2767.","journal-title":"J Clin Oncol"},{"key":"1037_CR31","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.3747\/co.2007.152","volume":"14","author":"C Thorne","year":"2007","unstructured":"Thorne C. Management of arthralgias associated with aromatase inhibitor therapy. Curr Oncol. 2007;14:S11\u2013S9.","journal-title":"Curr Oncol"},{"issue":"25","key":"1037_CR32","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1200\/JCO.2007.10.7573","volume":"25","author":"KD Crew","year":"2007","unstructured":"Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877\u201383.","journal-title":"J Clin Oncol"},{"issue":"17","key":"1037_CR33","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1016\/j.ejca.2006.07.005","volume":"42","author":"J Geisler","year":"2006","unstructured":"Geisler J, Lonning PE, Krag LE, et al. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. Eur J Cancer. 2006;42(17):2968\u201375. Epub 006 Sep 11.","journal-title":"Eur J Cancer"},{"key":"1037_CR34","first-page":"S137","volume":"88","author":"M Taylor","year":"2004","unstructured":"Taylor M, Rastelli A, Civitelli R, Ellis M. Incidence of 25-OH vitamin D deficiency in patients with a history of breast cancer who have musculoskeletal symptomatology. Breast Cancer Res Treat. 2004;88:S137.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1037_CR35","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.breast.2007.01.011","volume":"16","author":"HJ Burstein","year":"2007","unstructured":"Burstein HJ. Aromatase inhibitor-associated arthralgia syndrome. The Breast. 2007;16(3):223\u201334.","journal-title":"The Breast"},{"issue":"Suppl 1","key":"1037_CR36","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.3747\/co.2007.151","volume":"14","author":"C Derzko","year":"2007","unstructured":"Derzko C, Elliott S, Lam W. Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr Oncol. 2007;14(Suppl 1):S20\u201340.","journal-title":"Curr Oncol"},{"issue":"21","key":"1037_CR37","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2004.08.029","volume":"22","author":"L Fallowfield","year":"2004","unstructured":"Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol. 2004;22(21):4261\u201371.","journal-title":"J Clin Oncol"},{"issue":"28","key":"1037_CR38","doi-asserted-by":"crossref","first-page":"6931","DOI":"10.1200\/JCO.2005.11.181","volume":"23","author":"TJ Whelan","year":"2005","unstructured":"Whelan TJ, Goss PE, Ingle JN, et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5\u00a0years of tamoxifen in postmenopausal women. J Clin Oncol. 2005;23(28):6931\u201340. Epub 2005 Sep 12.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1037_CR39","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ygyno.2004.02.001","volume":"93","author":"ML Krychman","year":"2004","unstructured":"Krychman ML, Carter J, Aghajanian CA, Dizon DS, Castiel M. Chemotherapy-induced dyspareunia: a case study of vaginal mucositis and pegylated liposomal doxorubicin injection in advanced stage ovarian carcinoma. Gynecol Oncol. 2004;93(2):561\u20133.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1037_CR40","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women\u2019s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321\u201333.","journal-title":"JAMA"},{"issue":"25","key":"1037_CR41","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1056\/NEJMoa071513","volume":"356","author":"JE Manson","year":"2007","unstructured":"Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007;356(25):2591\u2013602.","journal-title":"N Engl J Med"},{"issue":"36","key":"1037_CR42","doi-asserted-by":"crossref","first-page":"5715","DOI":"10.1200\/JCO.2007.12.1665","volume":"25","author":"H Mouridsen","year":"2007","unstructured":"Mouridsen H, Keshaviah A, Coates AS, et al. Cardiovascular Adverse Events During Adjuvant Endocrine Therapy for Early Breast Cancer Using Letrozole or Tamoxifen: Safety Analysis of BIG 1\u201398 Trial. J Clin Oncol. 2007;25(36):5715\u201322.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1037_CR43","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1200\/JCO.2007.14.0459","volume":"26","author":"D Crivellari","year":"2008","unstructured":"Crivellari D, Sun Z, Coates AS, et al. Letrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1\u201398 Trial. J Clin Oncol. 2008;26(12):1972\u20139.","journal-title":"J Clin Oncol"},{"key":"1037_CR44","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/cncr.24219","volume":"115","author":"M Ewer","year":"2009","unstructured":"Ewer M, Gluck S. A women\u2019s heart: the impact of adjuvant endocrine therapy on cardiovascular health. Cancer. 2009;115:1813\u201326.","journal-title":"Cancer"},{"key":"1037_CR45","unstructured":"Ewer M, Gluck S. Evaluation of lipid profiles and cardiovascular (CV) safety data of aromatase inhibitors (AI). In: American Society of Clinical Oncology; 2008; Washington DC; 2008."},{"issue":"9","key":"1037_CR46","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2165\/00002018-200629090-00003","volume":"29","author":"J-M Nabholtz","year":"2006","unstructured":"Nabholtz J-M, Gligorov J. Cardiovascular Safety Profiles of Aromatase Inhibitors: A Comparative Review. Drug Safety. 2006;29(9):785.","journal-title":"Drug Safety"},{"issue":"5","key":"1037_CR47","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/annonc\/mdi158","volume":"16","author":"KM Wasan","year":"2005","unstructured":"Wasan KM, Goss PE, Pritchard PH, et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5\u00a0years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol. 2005;16(5):707\u201315.","journal-title":"Ann Oncol"},{"issue":"3","key":"1037_CR48","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF00713400","volume":"36","author":"T Engan","year":"1995","unstructured":"Engan T, Krane J, Johannessen DC, Lonning PE, Kvinnsland S. Plasma changes in breast cancer patients during endocrine therapy\u2013lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Res Treat. 1995;36(3):287\u201397.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"1037_CR49","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/annonc\/mdh064","volume":"15","author":"G Atalay","year":"2004","unstructured":"Atalay G, Dirix L, Biganzoli L, et al. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, \u2018Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients\u2019. Ann Oncol. 2004;15(2):211\u20137.","journal-title":"Ann Oncol"},{"key":"1037_CR50","unstructured":"New research shows no link between aromatase inhibitors and cardiovascular problems. 2008. (Accessed November 23, 2008, at http:\/\/www.ecco-org.eu\/News\/Press-room\/Press-release .)"},{"key":"1037_CR51","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S0002-8223(99)00298-9","volume":"99","author":"CL Rock","year":"1999","unstructured":"Rock CL, Flatt SW, Newman V, et al. Factors associated with weight gain in women after diagnosis of breast cancer. Women\u2019s healthy eating and living study group. Am Diet Assoc. 1999;99:1212\u201321.","journal-title":"Am Diet Assoc."},{"key":"1037_CR52","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/cncr.11227","volume":"97","author":"ML Irwin","year":"2003","unstructured":"Irwin ML, Crumley D, McTiernan A, et al. Physical activity levels before and after a diagnosis of breast carcinoma: the Health, Eating, Activity, and Lifestyle (HEAL) study. Cancer. 2003;97:1746\u201357.","journal-title":"Cancer"},{"issue":"10","key":"1037_CR53","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/jnci\/djj188","volume":"98","author":"JA Cauley","year":"2006","unstructured":"Cauley JA, McTiernan A, Rodabough RJ, et al. Statin Use and Breast Cancer: Prospective Results From the Women\u2019s Health Initiative. J Natl Cancer Inst. 2006;98(10):700\u20137.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"1037_CR54","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1089\/jwh.2006.0047","volume":"16","author":"SA Norman","year":"2007","unstructured":"Norman SA, Potashnik SL, Galantino MG, De Michele AM, House L, Localio AR. Modifiable risk factors for breast cancer recurrence: what can we tell survivors? Journal of Womens Health. 2007;16(2):117\u201390.","journal-title":"Journal of Womens Health"},{"issue":"2","key":"1037_CR55","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1210\/er.2001-0016","volume":"24","author":"BB Sherwin","year":"2003","unstructured":"Sherwin BB. Estrogen and Cognitive Functioning in Women. Endocr Rev. 2003;24(2):133\u201351.","journal-title":"Endocr Rev"},{"issue":"9","key":"1037_CR56","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1001\/jama.279.9.688","volume":"279","author":"K Yaffe","year":"1998","unstructured":"Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen Therapy in Postmenopausal Women: Effects on Cognitive Function and Dementia. JAMA. 1998;279(9):688\u201395.","journal-title":"JAMA"},{"issue":"20","key":"1037_CR57","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1001\/jama.289.20.2663","volume":"289","author":"SR Rapp","year":"2003","unstructured":"Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women\u2019s Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289(20):2663\u201372.","journal-title":"JAMA"},{"issue":"24","key":"1037_CR58","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.291.24.2947","volume":"291","author":"SA Shumaker","year":"2004","unstructured":"Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women\u2019s Health Initiative Memory Study. JAMA. 2004;291(24):2947\u201358.","journal-title":"JAMA"},{"issue":"2","key":"1037_CR59","first-page":"127","volume":"106","author":"SA Reid-Arndt","year":"2009","unstructured":"Reid-Arndt SA. Breast cancer and chemobrain: the consequences of cognitive difficulties following chemotherapy and the potential for recovery. Mo Med. 2009;106(2):127\u201331.","journal-title":"Mo Med"},{"issue":"6","key":"1037_CR60","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1053\/j.seminoncol.2003.09.008","volume":"30","author":"HS Rugo","year":"2003","unstructured":"Rugo HS, Ahles T. The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research. Seminars in Oncology. 2003;30(6):749\u201362.","journal-title":"Seminars in Oncology"},{"issue":"6","key":"1037_CR61","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1097\/gme.0b013e318148b28b","volume":"14","author":"CM Bender","year":"2007","unstructured":"Bender CM, Sereika SM, Brufsky AM, et al. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause. 2007;14(6):995\u20138.","journal-title":"Menopause"},{"issue":"1","key":"1037_CR62","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1677\/ERC-07-0193","volume":"15","author":"P Hadji","year":"2008","unstructured":"Hadji P. Menopausal symptoms and adjuvant therapy-associated adverse events. Endocr Relat Cancer. 2008;15(1):73\u201390.","journal-title":"Endocr Relat Cancer"},{"issue":"S1","key":"1037_CR63","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1038\/sj.bjc.6602692","volume":"93","author":"NJ Bundred","year":"2005","unstructured":"Bundred NJ. The effects of aromatase inhibitors on lipids and thrombosis. Br J Cancer. 2005; 93S1: S23\u20137.","journal-title":"Br J Cancer"},{"issue":"1","key":"1037_CR64","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","volume":"9","author":"The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists\u2019 Group","year":"2008","unstructured":"The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists\u2019 Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. The Lancet Oncol. 2008;9(1):45\u201353.","journal-title":"The Lancet Oncol."},{"key":"1037_CR65","doi-asserted-by":"crossref","unstructured":"Coombes R, Kilburn L, Snowdon C, et al. Survival and safety of exemestane versus tamoxifen after 2\u20133\u00a0years\u2019 tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. The Lancet. 2007;(369):559\u201370.","DOI":"10.1016\/S0140-6736(07)60200-1"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-009-1037-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11606-009-1037-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-009-1037-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T14:02:13Z","timestamp":1634047333000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11606-009-1037-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,18]]},"references-count":65,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["1037"],"URL":"https:\/\/doi.org\/10.1007\/s11606-009-1037-2","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,18]]}}}